Filters
cris logo
-
New search Filters
Select from list
Displayed from Show more
You have reached the maximum number of displayed search results.
All results displayed
No results are available for the search performed
Displayed from
You have reached the maximum number of displayed search results.
All results displayed
Loading results
Obtaining statistical data

Projects / Programmes source: ARIS

Optimization of MDP and TNF analogues having therapeutic potential

Edit
Research activity

Code Science Field Subfield
1.09.00  Natural sciences and mathematics  Pharmacy   

Code Science Field
B470  Biomedical sciences  Physiology 
B500  Biomedical sciences  Immunology, serology, transplantation 
Keywords
Analogues, TNF-alpha, MDP, antitumor activity, immunomodulators, immunorestoration, immunosuppression, drugs
Evaluation (rules)
source: COBISS
Evaluation of bibliographic research performance indicators according to ARIS methodology
Citations Citations for bibliographic records in COBIB.SI that are linked to records in citation databases
source: WoS source: Scopus source: COBISS
Researchers (26)
no. Code Name and surname Research area Role Period No. of publications
1.  03286  Vera Čoroli  Oncology  Researcher  1998 - 2000  1 
2.  04652  MSc Borut Furlan  Chemistry  Researcher  1998 - 2000  99 
3.  06108  PhD Vladimira Gaberc-Porekar  Biotechnology  Researcher  1998 - 2000  220 
4.  15284  PhD Stanislav Gobec  Pharmacy  Researcher  1998 - 2000  837 
5.  01302  PhD Matjaž Jeras  Biotechnology  Researcher  1998 - 2000  363 
6.  17275  Ana Marija Jesenko    Researcher  1998 - 2000  0 
7.  16171  PhD Simona Jevševar  Biotechnology  Researcher  1998 - 2000  51 
8.  07822  Alenka Kanalec  Pharmacy  Researcher  1998 - 2000  6 
9.  12942  PhD Janez Kerč  Pharmacy  Researcher  1998 - 2000  240 
10.  01463  PhD Danijel Kikelj  Pharmacy  Researcher  1998 - 2000  566 
11.  00385  PhD Nada Kraševec  Biotechnology  Researcher  1998 - 2000  214 
12.  00839  PhD Aleš Krbavčič  Pharmacy  Researcher  1998 - 2000  344 
13.  09924  PhD Anton Lavrič  Pharmacy  Researcher  1998 - 2000  57 
14.  17276  Jelka Lenarčič    Researcher  1998 - 2000  2 
15.  01494  PhD Viktor Menart  Biotechnology  Researcher  1998 - 2000  162 
16.  17437  Marjeta Mulej    Researcher  1998 - 2000  0 
17.  08007  PhD Srdjan Novaković  Oncology  Researcher  1998 - 2000  496 
18.  03070  PhD Slavko Pečar  Pharmacy  Researcher  1998 - 2000  415 
19.  08800  PhD Gregor Serša  Oncology  Researcher  1998 - 2000  1,511 
20.  08519  PhD Marija Sollner Dolenc  Pharmacy  Researcher  1998 - 2000  658 
21.  00830  PhD Anton Štalc  Biotechnology  Head  1998 - 2000  158 
22.  01878  PhD Uroš Urleb  Pharmacy  Researcher  1998 - 2000  380 
23.  10453  PhD Blanka Vidan-Jeras  Microbiology and immunology  Researcher  1998 - 2000  136 
24.  09963  Andreja Vukmirovič  Pharmacy  Researcher  1998 - 2000  0 
25.  17438  Damijana Zalar    Researcher  1998 - 2000  0 
26.  04651  MSc Teofil Žižek  Chemistry  Researcher  1998 - 2000  14 
Organisations (5)
no. Code Research organisation City Registration number No. of publications
1.  0104  National Institute of Chemistry  Ljubljana  5051592000  20,996 
2.  0258  Lek Pharmaceutical Company d.d.  Ljubljana  1732811  8,438 
3.  0302  Institute of Oncology Ljubljana  Ljubljana  5055733000  15,468 
4.  0311  Blood Transfusion Centre of Slovenia  Ljubljana  5053960  1,737 
5.  0787  University of Ljubljana, Faculty of Pharmacy  Ljubljana  1626973  17,172 
Abstract
On the basis of the previous projects about 100 desmuramyl analogues of muramyl dipeptide have been synthesized and evaluated; two analogues have a potential for the therapy of immunological diseases. The present project is directed to those technological and medical studies of two analogues which could contribute to the development of the final drug. On the other handžwe discovered, during development of tumor necrosis factor (TNF) analogues, a region on its molecule where replacement of certain amino acid residues can lead to new molecules having improved activity with reduced systemic toxicity. New TNF analogues will be developed and tested for their anti-tumor activity.
Confirmation required
Views history
Favourite